ArticleScientific reports2026
Astaxanthin improve the intestinal microbiota and metabolism after ischemic stroke.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
As a prevalent cerebrovascular disorder, the association between ischemic stroke and gut microbiota has garnered increasing attention. Recent studies have confirmed that astaxanthin exhibits significant protective effects against ischemic stroke. However, there is still a lack of clear experimental evidence regarding whether astaxanthin can regulate the gut microbiota in patients with ischemic stroke. To investigate the neuroprotective mechanism of astaxanthin and its regulatory effect on gut microbiota, a rat stroke model was established using the middle cerebral artery occlusion method. Molecular docking and molecular dynamics were used to verify the binding stability of energy metabolism-related proteins with astaxanthin. The intervention effects of astaxanthin on ischemic brain injury were systematically evaluated through histopathological analysis (hematoxylin-eosin staining) and molecular biology assays (ELISA and Western blot). Additionally, the composition of gut microbiota was analyzed using 16 S rRNA high-throughput sequencing technology, combined with untargeted metabolomics methods, to comprehensively elucidate the regulatory effects of astaxanthin on brain metabolites, thereby clarifying its potential molecular mechanisms. Astaxanthin intervention significantly altered the structure of the gut microbiota, characterized by an increase in beneficial bacteria and a decrease in pathogenic bacteria, which concurrently led to marked changes in brain metabolites. The results of molecular docking and molecular dynamics show that astaxanthin has stable binding to the energy metabolism proteins AMPK and SIRT1. This protective mechanism not only improved the energy metabolism levels under ischemic stroke conditions but also involved the upregulation of AMPK and SIRT1 expression. The current research shows that astaxanthin may exert neuroprotective effects against ischemic stroke through the AMPK/SIRT1 signaling pathway, with its mechanism involving the regulation of gut microbiota and their metabolic products. Based on this finding, this compound holds significant research value as a potential therapeutic agent, warranting further exploration and validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.